Get the Stockscreener App
0.26
1.59%
-0.0042
After Hours:
.27
0.01
+3.85%
Applied Therapeutics Inc stock is traded at $0.26, with a volume of 4.57M.
It is down -1.59% in the last 24 hours and down -80.00% over the past month.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
See More
Previous Close:
$0.2642
Open:
$0.264
24h Volume:
4.57M
Relative Volume:
0.38
Market Cap:
$37.52M
Revenue:
-
Net Income/Loss:
$-119.76M
P/E Ratio:
-0.1926
EPS:
-1.35
Net Cash Flow:
$-55.17M
1W Performance:
+0.50%
1M Performance:
-80.00%
6M Performance:
-31.05%
1Y Performance:
-96.97%
1-Day Range:
$0.2541
$0.2656
1-Week Range:
$0.238
$0.2698
52-Week Range:
$0.2182
$2.44
Applied Therapeutics Inc Stock (APLT) Company Profile
Name
Applied Therapeutics Inc
Sector
Industry
Phone
212-220-9226
Address
545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY
Compare APLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLT
Applied Therapeutics Inc
|
0.26 | 38.12M | 0 | -119.76M | -55.17M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-02-24 | Downgrade | UBS | Buy → Neutral |
| Nov-29-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-31-24 | Initiated | William Blair | Outperform |
| Mar-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-22-24 | Initiated | Leerink Partners | Outperform |
| Jan-04-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Aug-27-21 | Downgrade | Goldman | Neutral → Sell |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Oct-08-20 | Initiated | Truist | Buy |
| Apr-22-20 | Initiated | Goldman | Buy |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jun-10-19 | Initiated | Citigroup | Buy |
| Jun-10-19 | Initiated | Cowen | Outperform |
| Jun-10-19 | Initiated | Robert W. Baird | Outperform |
View All
Applied Therapeutics Inc Stock (APLT) Latest News
What analysts say about Applied Therapeutics Inc stockHead and Shoulders Patterns & Minimal Investment Trading - earlytimes.in
Applied Therapeutics (APLT) Upgraded to Buy: Here's Why - Yahoo Finance
Applied Therapeutics Reports Third Quarter 2025 Financial Results - ADVFN
Applied Therapeutics To Lay Off Nearly Half Its Staff, Board Explores M&A Options - MSN
Applied Therapeutics (APLT) Stock Price, Quote, News & History - Benzinga
Applied Therapeutics Investors Get 1st OK For $15M Deal - Law360
Why Applied Therapeutics Inc. stock could see breakout soonMarket Trend Review & Weekly Momentum Stock Picks - newser.com
Applied Therapeutics explores strategic alternatives amid workforce cuts By Investing.com - Investing.com Nigeria
Applied Therapeutics Announces Corporate Updates - Investing News Network
Applied Therapeutics, Inc. Initiates Strategic Alternatives Review - TradingView
Applied Therapeutics explores strategic alternatives amid workforce cuts - Investing.com
APLT Evaluates Strategic Options as Workforce Reductions Announced - GuruFocus
APLT Evaluates FDA Meeting Outcomes for Govorestat Development P - GuruFocus
What data driven models say about Applied Therapeutics Inc.’s future - newser.com
Applied Therapeutics (Nasdaq: APLT) to Explore Strategic Alternatives, Reduce Workforce 46% - Stock Titan
Can Applied Therapeutics Inc. (2UV) stock surprise markets with earningsMarket Volume Report & High Win Rate Trade Tips - newser.com
Is Applied Therapeutics Inc. (2UV) stock prepared for digital transitionMarket Sentiment Review & Growth Focused Stock Pick Reports - newser.com
How Applied Therapeutics Inc. stock reacts to inflationary pressuresWeekly Trade Analysis & High Accuracy Swing Entry Alerts - newser.com
Can Applied Therapeutics Inc. (2UV) stock expand revenue streamsJuly 2025 Breakouts & Safe Swing Trade Setups - newser.com
Is Applied Therapeutics Inc. (2UV) stock a top pick for value investorsEarnings Risk Report & Detailed Earnings Play Strategies - newser.com
Why Applied Therapeutics Inc. (2UV) stock fits value portfoliosVolume Spike & Free Daily Entry Point Trade Alerts - newser.com
Applied Therapeutics Inc. stock daily chart insightsJuly 2025 Pullbacks & Expert Verified Movement Alerts - newser.com
Does Applied Therapeutics Inc. show high probability of reboundJuly 2025 Earnings & Smart Investment Allocation Insights - newser.com
Statistical indicators supporting Applied Therapeutics Inc.’s strengthPortfolio Update Report & Low Drawdown Investment Strategies - newser.com
Analyzing Applied Therapeutics Inc. with multi timeframe chartsEarnings Summary Report & Fast Moving Trade Plans - newser.com
Published on: 2025-11-19 00:29:12 - newser.com
Applied Therapeutics Inc Stock (APLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):